Bank of America spends approximately $250 million or more each year on GLP-1 weight-loss medications for its employees [1].
The expenditure highlights the growing financial impact of weight-loss drugs like Ozempic and Wegovy on corporate healthcare budgets. As companies grapple with the high cost of these treatments, the bank's approach suggests a shift toward viewing obesity treatment as a productivity tool rather than a mere expense.
Chief Executive Officer Brian Moynihan discussed the spending during an interview on CNBC's "Squawk Box" on Wednesday. He said the investment is aimed at improving the overall health of the workforce. According to Moynihan, the costs are justified because they lead to better health outcomes for the staff.
"We spend about $250 million or more on GLP-1 drugs each year," Moynihan said [1].
The spending represents approximately 13% of the bank's total healthcare spend [2]. This significant allocation comes as GLP-1 medications have seen a surge in popularity for treating obesity and type 2 diabetes. Moynihan said the expenditure is a good investment in workforce health and productivity [3].
Despite the benefits, the CEO acknowledged the risks associated with employee turnover. He said he knows some employees will leave the company before they can reap the full health benefits of the medication [4]. This turnover creates a financial risk for the company, as it pays for the treatment without seeing the long-term reduction in healthcare costs that typically follows successful weight loss.
However, the bank continues to support the coverage. Moynihan said the decision is rooted in the belief that a healthier workforce is more efficient, and more likely to remain with the firm over the long term [3].
“We spend about $250 million or more on GLP-1 drugs each year.”
The scale of Bank of America's spending indicates that GLP-1 drugs are becoming a primary driver of corporate health insurance costs. By allocating 13% of its healthcare budget to these medications, the bank is betting that the long-term reduction in chronic diseases—such as heart disease and diabetes—will offset the immediate high cost of the drugs and the risk of employee attrition.
